Raphael Benjamin J, Volik Stanislav, Yu Peng, Wu Chunxiao, Huang Guiqing, Linardopoulou Elena V, Trask Barbara J, Waldman Frederic, Costello Joseph, Pienta Kenneth J, Mills Gordon B, Bajsarowicz Krystyna, Kobayashi Yasuko, Sridharan Shivaranjani, Paris Pamela L, Tao Quanzhou, Aerni Sarah J, Brown Raymond P, Bashir Ali, Gray Joe W, Cheng Jan-Fang, de Jong Pieter, Nefedov Mikhail, Ried Thomas, Padilla-Nash Hesed M, Collins Colin C
Department of Computer Science & Center for Computational Molecular Biology, Brown University, Waterman Street, Providence, RI 02912-1910, USA.
Genome Biol. 2008;9(3):R59. doi: 10.1186/gb-2008-9-3-r59. Epub 2008 Mar 25.
The genomes of many epithelial tumors exhibit extensive chromosomal rearrangements. All classes of genome rearrangements can be identified using end sequencing profiling, which relies on paired-end sequencing of cloned tumor genomes.
In the present study brain, breast, ovary, and prostate tumors, along with three breast cancer cell lines, were surveyed using end sequencing profiling, yielding the largest available collection of sequence-ready tumor genome breakpoints and providing evidence that some rearrangements may be recurrent. Sequencing and fluorescence in situ hybridization confirmed translocations and complex tumor genome structures that include co-amplification and packaging of disparate genomic loci with associated molecular heterogeneity. Comparison of the tumor genomes suggests recurrent rearrangements. Some are likely to be novel structural polymorphisms, whereas others may be bona fide somatic rearrangements. A recurrent fusion transcript in breast tumors and a constitutional fusion transcript resulting from a segmental duplication were identified. Analysis of end sequences for single nucleotide polymorphisms revealed candidate somatic mutations and an elevated rate of novel single nucleotide polymorphisms in an ovarian tumor.
These results suggest that the genomes of many epithelial tumors may be far more dynamic and complex than was previously appreciated and that genomic fusions, including fusion transcripts and proteins, may be common, possibly yielding tumor-specific biomarkers and therapeutic targets.
许多上皮肿瘤的基因组表现出广泛的染色体重排。所有类型的基因组重排都可以通过末端测序分析来识别,该方法依赖于对克隆的肿瘤基因组进行双末端测序。
在本研究中,使用末端测序分析对脑、乳腺、卵巢和前列腺肿瘤以及三种乳腺癌细胞系进行了检测,获得了最大的可用于测序的肿瘤基因组断点集合,并提供了证据表明某些重排可能是反复出现的。测序和荧光原位杂交证实了易位以及复杂的肿瘤基因组结构,其中包括不同基因组位点的共扩增和包装以及相关的分子异质性。肿瘤基因组的比较表明存在反复出现的重排。有些可能是新的结构多态性,而其他的可能是真正的体细胞重排。在乳腺肿瘤中鉴定出一种反复出现的融合转录本以及由节段性重复产生的一种组成性融合转录本。对单核苷酸多态性的末端序列分析揭示了候选体细胞突变以及卵巢肿瘤中新型单核苷酸多态性的发生率升高。
这些结果表明,许多上皮肿瘤的基因组可能比以前认为的更加动态和复杂,并且基因组融合,包括融合转录本和蛋白质,可能很常见,这可能会产生肿瘤特异性生物标志物和治疗靶点。